GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Stories, insights,
and updates.

Clinical insights, research updates, and conference highlights in gastroenterology — page 5.

The Future of Gastroenterology Intelligence: How HIPAA-Ready, GI-Specialized AI Is Reshaping Care

The Future of Gastroenterology Intelligence: How HIPAA-Ready, GI-Specialized AI Is Reshaping Care

Gastroenterology has become an information-dense specialty. Clinicians are expected to synthesize expanding biomedical literature, rapidly changing GI guidelines, EHR data, pathology, imaging, endoscopy findings, and late-breaking conference updates while still making safe, time-sensitive decisions at the bedside and in the endoscopy suite. That challenge is not unique to GI, but it is especially visible in a field that spans hepatology, inflammatory bowel disease, GI oncology, screening and surveillance, pancreaticobiliary disease, motility, nutrition, and complex procedural care. Reviews of healthcare information overload and EHR-related cognitive burden have linked this environment to workflow strain and patient-safety risk, while PubMed alone now indexes more than 40 million biomedical citations. [1]The strategic opportunity is not “more AI” in the abstract. It is better clinical intelligence: HIPAA-ready AI that is specialized for gastroenterology, grounded in current society guidance, designed for human oversight, and capable of adapting its output to the user’s role. Recent reviews across NIH/PubMed, WJGNet, Gastroenterology, AMEgroups, and ScienceDirect describe real momentum for gastroenterology AI in endoscopy, IBD, hepatology, oncology, decision support, and education, but they also emphasize unresolved issues around hallucination, liability, bias, interoperability, and real-world validation. [2]The editorial implication is straightforward: generic search and general-purpose language models are not enough for high-stakes GI care. A safer path is GI-specialized, mode-adaptive, governed deployment. In practical terms, that means systems that can support gastroenterology education for fellows, GI clinical decision support for specialists, and responsible patient-facing communication—while respecting HIPAA, working within EHR interoperability standards, and remaining subordinate to clinician judgment. [3]

June 1, 2026•GastroAGI Team
Read Now20views
HER2-Positive Gastroesophageal Cancer in 2026: How HERIZON-GEA-01 Resets the First-Line Standard

HER2-Positive Gastroesophageal Cancer in 2026: How HERIZON-GEA-01 Resets the First-Line Standard

A 58-year-old male presents with progressive dysphagia, a 9 kg weight loss over three months, and a biopsy-confirmed HER2-positive gastroesophageal junction adenocarcinoma. Staging shows liver metastases. His PD-L1 combined positive score comes back at 2. Until last week, this was a trastuzumab-plus-chemotherapy case with a few nuanced arguments for adding pembrolizumab. The HERIZON-GEA-01 trial, published in the New England Journal of Medicine on May 28, 2026, changed the conversation for exactly this patient.HER2-positive disease accounts for approximately 20% of gastroesophageal adenocarcinoma (GEA) cases, and it has carried a disproportionately poor prognosis despite the availability of targeted therapy. Trastuzumab became the first-line backbone after the ToGA trial in 2010 - a result built on a modest overall survival benefit of roughly 2.7 months. For 16 years, that modest gain was the ceiling. The clinical question driving HERIZON-GEA-01 was straightforward: can a dual HER2-targeting bispecific antibody built to hit two non-overlapping epitopes simultaneously outperform a single-domain binder that has been the standard since gastroesophageal oncology was a subspecialty niche? And does adding a PD-1 checkpoint inhibitor extend that benefit further - including in patients whose tumours don't express PD-L1? Much like resmetirom becoming the first approved drug for NASH with fibrosis rewrote the MASLD treatment algorithm, the answer to both questions here reshapes the first-line standard for HER2-positive GEA. Based on zanidatamab HER2-positive gastroesophageal cancer first-line treatment data from 914 patients across three continents, the answer to both is yes.

June 1, 2026•GastroAGI Team
Read Now17views
FIB-4 in MASLD: When to Trust It, When It Fails, and What to Do in the Grey Zone

FIB-4 in MASLD: When to Trust It, When It Fails, and What to Do in the Grey Zone

Your patient is a 54-year-old woman with type 2 diabetes, a BMI of 33, and incidentally detected hepatic steatosis on abdominal ultrasound. You calculate her FIB-4 - it comes back at 1.1, which puts her in the low-risk category. You file it, reassure her, and plan a repeat in a year. Two years later she re-presents with fatigue and a platelet count of 118. Her FibroScan shows liver stiffness of 11.2 kPa. She has bridging fibrosis. The FIB-4 missed it. This post explains exactly why, and what your workup should have looked like.

May 25, 2026•GastroAGI Team
Read Now25views
Hepatic Encephalopathy in 2026: What the New ACG Guideline Changes About How You Diagnose, Treat, and Prevent It

Hepatic Encephalopathy in 2026: What the New ACG Guideline Changes About How You Diagnose, Treat, and Prevent It

Your cirrhotic patient is confused. Ammonia is elevated. You start lactulose and order a CT head out of habit. If that sequence sounds familiar, the new ACG hepatic encephalopathy guideline - published in March 2026 - is going to make you rethink several of those reflexes. Here is what changed, what stayed the same, and what it means for the patient in front of you tonight.Hepatic encephalopathy remains one of the most clinical challenging complications of cirrhosis - not because the diagnosis is obscure, but because the spectrum from covert to overt disease is wider than most clinicians manage systematically. The 2026 ACG guideline is the first to consolidate diagnosis, inpatient management, recurrence prevention, nutrition, TIPS-related HE, and transplant access into a single GRADE-based framework. Before this guideline, most clinicians were working from fragmented guidance across AASLD, EASL, and institutional protocols. The 24 recommendations now provide a unified, evidence-ranked reference for the full clinical journey.This is not a marginal update. Several recommendations directly contradict common practice.

May 22, 2026•GastroAGI Team
Read Now21views
ESGE Days 2026 Milan: What Every Gastroenterologist Needs to Take Back to Practice

ESGE Days 2026 Milan: What Every Gastroenterologist Needs to Take Back to Practice

Over 5,000 endoscopists descended on Milan's Allianz MiCo Convention Centre from May 14–16 for what has become the most important GI endoscopy congress in Europe. Three days, 44 educational sessions, live endoscopy from the Humanitas University Medical School, landmark trial data, and a record-breaking abstract haul. If you weren't there - or if you were and couldn't see everything - here is the clinical substance that matters.ESGE Days 2026 marked a turning point in several areas simultaneously: the obesity space was shaken by a head-to-head comparison between endoscopic sleeve gastroplasty and oral semaglutide, new randomised data landed for Crohn's strictures and gastroparesis, and the society formally launched three Special Interest Groups that will define the agenda for the next decade. The breadth of the scientific programme - from yoga in the endoscopy unit to robotic ERCP - reflected just how rapidly the field is evolving. Not every session changes practice immediately, but several clearly will.

May 21, 2026•GastroAGI Team
Read Now14views
Obesity is Plateauing in the West and Accelerating Everywhere Else: What That Means for Clinical Practice

Obesity is Plateauing in the West and Accelerating Everywhere Else: What That Means for Clinical Practice

A 34-year-old woman from a Pacific Island nation presents with a BMI of 38, type 2 diabetes diagnosed two years ago, and a haemoglobin of 9.4 g/dL. She has visible signs of iron and B12 deficiency alongside frank visceral obesity. She is, in nutritional terms, both overnourished and undernourished simultaneously. This is not an edge case anymore - it is the clinical reality of obesity in 2026 across much of the low- and middle-income world, and treating only one half of the picture will fail the patient.The largest epidemiological analysis of obesity ever published - the NCD Risk Factor Collaboration's 2026 study in Nature, tracking 232 million individuals across 200 countries from 1980 to 2024 - does not just tell us where obesity is. It tells us how fast it is moving, and which populations are now past the inflection point. The findings have direct implications for how gastroenterologists and GI clinicians approach obesity-related disease in patients coming from different epidemiological backgrounds.

May 20, 2026•GastroAGI Team
Read Now11views
Obesity Pharmacotherapy in 2026: How EASO's Complication-First Framework Changes the Way You Choose a Drug

Obesity Pharmacotherapy in 2026: How EASO's Complication-First Framework Changes the Way You Choose a Drug

Your patient has a BMI of 34, MASLD on ultrasound, and an HbA1c of 6.8%. You reach for a GLP-1 - but which one? For what endpoint? And what counts as treatment success? Until recently, the default answer was "the one that causes the most weight loss." The EASO 2026 framework formally dismantles that logic.

May 18, 2026•GastroAGI Team
Read Now11views
H. pylori Treatment in 2026: Choosing the Right First-Line Regimen When Clarithromycin Is No Longer the Default

H. pylori Treatment in 2026: Choosing the Right First-Line Regimen When Clarithromycin Is No Longer the Default

Your patient tests positive for H. pylori - straightforward PPI + clarithromycin + amoxicillin, right? Not anymore. Clarithromycin resistance has crossed 15–20% in most urban centres, and PPI triple therapy now fails in roughly one in four patients before you even factor in CYP2C19 metabolism. The 2026 ACG guideline has moved the goalposts on first-line treatment, and if you're still reaching for the old triple automatically, this post is for you.

May 13, 2026•GastroAGI Team
Read Now217views
DDW 2026 Highlights: Day-by-Day Conference Insights for Gastroenterologists

DDW 2026 Highlights: Day-by-Day Conference Insights for Gastroenterologists

You couldn't be everywhere at DDW 2026. Four days, hundreds of sessions, thousands of attendees across McCormick Place - and the signal-to-noise ratio was unforgiving. This post cuts straight to what mattered: the clinical themes that surfaced repeatedly, the practice-changing debates, and the takeaways that will follow you into clinic long after the Chicago wind fades. Day by day.

May 11, 2026•GastroAGI Team
Read Now24views
Daraxonrasib in Previously Treated RAS-Mutated Pancreatic Cancer: What the NEJM Phase 1/2 Data Actually Means

Daraxonrasib in Previously Treated RAS-Mutated Pancreatic Cancer: What the NEJM Phase 1/2 Data Actually Means

A 61-year-old woman with metastatic pancreatic ductal adenocarcinoma has progressed through FOLFIRINOX. Her KRAS mutation is G12D - not G12C, which means sotorasib and adagrasib are off the table. Until recently, your only option was nanoliposomal irinotecan plus 5-FU or enrollment in a clinical trial, with an expected median overall survival of five to seven months. The Phase 1/2 daraxonrasib trial published in the New England Journal of Medicine in May 2026 changes the calculus.The second-line treatment landscape for pancreatic ductal adenocarcinoma (PDAC) has been defined by futility for decades. Fewer than 10% of patients respond to second-line chemotherapy, and median survival after progression on first-line therapy sits at five to seven months. KRAS inhibitors disrupted this ceiling in lung cancer, but pancreatic cancer posed a harder problem - the mutations are different, they're more heterogeneous, and KRAS drives PDAC in its active, GTP-bound "on" state rather than the inactive state targeted by earlier inhibitors. Daraxonrasib is the first RAS(ON) multi-selective inhibitor to enter clinical trials for PDAC, and the results out of this first-in-human trial represent the most credible survival signal this disease has seen in a very long time.

May 8, 2026•GastroAGI Team
Read Now18views
Previous
14567
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer